What do rheumatoid arthritis nodules look like?

RA nodules are firm, round or oval subcutaneous lumps, usually ranging from a few millimeters to a couple of centimeters. They feel rubbery to hard and are typically mobile under the skin. They most commonly appear over pressure points like the elbow tip, finger joints, and the back of the heel. Unlike cysts, they don't contain fluid.

Do RA nodules go away on their own?

Some do, particularly if the underlying RA becomes better controlled with disease-modifying treatment. Others persist for years or indefinitely. Paradoxically, some patients develop more nodules after starting methotrexate - a documented phenomenon called methotrexate-induced nodulosis. Hydroxychloroquine has some evidence for nodule reduction in this situation.

Are RA nodules dangerous?

Most subcutaneous nodules are benign and primarily a cosmetic or minor functional concern. Nodules in unusual locations - lungs, vocal cords, eyes, or heart - are rarer and warrant monitoring. Any nodule that grows rapidly, becomes painful and red, or appears in an unusual location should be evaluated promptly by a rheumatologist.

Can you treat RA nodules without surgery?

Most RA nodules don't require surgical removal. Better systemic RA control can reduce or resolve some nodules over time. Local corticosteroid injection can shrink persistent symptomatic nodules. Surgery is reserved for nodules causing significant functional problems or breakdown risk. Recurrence after surgical removal is common.

Rheumatoid arthritis nodules: what they are, why they form, and what actually helps

Rheumatoid arthritis nodules are firm, subcutaneous lumps that develop in roughly 20-30% of RA patients - more commonly in those with seropositive (RF-positive) disease and higher overall disease activity. They’re one of the more visible extra-articular features of RA, and one of the things I hear about most from other patients who find a lump and don’t know what they’re looking at or whether to worry.

I’ve had RA for more than 30 years. Nodules are among the more puzzling and underexplained aspects of this disease - most patients don’t get a thorough explanation of what they are, why they formed, or what’s actually likely to help. The short answer is that most nodules are benign and primarily cosmetic, some respond to changes in disease management, and a small number in unusual locations do warrant closer attention.

What rheumatoid arthritis nodules actually are

RA nodules are not cysts (they don’t contain fluid), not tumors, and not infections. They’re organized immune lesions - structured collections of inflammatory cells arranged around a central zone of damaged tissue.

The microscopic structure is a granuloma: a core of fibrinoid necrosis surrounded by macrophages and fibroblasts arranged in a palisade pattern, with outer layers of lymphocytes and other inflammatory cells. This is the immune system organizing a chronic inflammatory response around tissue it has identified as damaged.

They develop at sites where mechanical stress and microvascular injury concentrate the immune complexes that trigger their formation. This is why they appear where they do - pressure points and friction sites where small blood vessels sustain repeated minor trauma. The distribution is not random; it follows the biomechanical logic of where the body takes repeated stress.

Who gets RA nodules and why

The strongest predictor is seropositivity - patients who are rheumatoid factor (RF) positive develop nodules far more commonly than seronegative patients. Anti-CCP positivity also correlates with nodule risk. Higher overall disease activity, longer disease duration, and more aggressive systemic inflammation all associate with greater nodule prevalence.

That said, seronegative RA patients do develop nodules occasionally, and not every seropositive patient with high disease activity develops them. Individual variation in how the immune system organizes local granulomatous responses appears to play a role we don’t fully understand yet.

Why nodules form: the mechanism

The central driver is immune complex deposition in small vessel walls. In seropositive RA, circulating immune complexes - including rheumatoid factor binding to IgG, and anti-CCP antibodies - deposit in the microvasculature at sites of mechanical stress. This triggers local complement activation and a cascade of inflammatory cell recruitment.

Macrophages arrive and begin engulfing debris from damaged vessel walls and surrounding tissue. Over weeks to months, the organized granulomatous structure develops - the classic palisade arrangement of macrophages around the necrotic center, with outer inflammatory infiltrate. The process is slow relative to other inflammatory events, which is why nodules typically take months to become noticeable after disease onset or a period of worsening inflammation.

The same mechanism that drives nodule formation in the skin - TNF-alpha, macrophage activation, granuloma organization - operates in other tissues, which explains why nodules occasionally develop in organs rather than just subcutaneous tissue.

Common locations and what to pay attention to

The most common sites are where anyone with RA would predict given the pressure-point mechanism: the olecranon bursa (the bony tip of the elbow), the extensor surfaces of the fingers and knuckles, the Achilles tendon and heel, and less commonly the back of the scalp.

Less common but documented locations: pulmonary nodules (often discovered incidentally on chest imaging done for other reasons), nodules on the vocal cords causing hoarseness, ocular nodules, and rarely cardiac nodules affecting valve tissue.

For the vast majority of patients, nodules are subcutaneous and cosmetic. The cases that warrant prompt evaluation are: rapid growth over days to weeks rather than months, redness and warmth suggesting infection or breakdown of the nodule surface, new nodules at unusual locations (any suspected internal site), or nodules at the heel causing significant pain with weight-bearing, which can become functionally limiting.

What treatments actually help - and the methotrexate paradox

The most reliable approach to RA nodules is treating the underlying RA effectively. Patients whose disease activity is well-controlled with effective DMARDs often see nodule regression over months to years as the inflammatory environment that sustains them is removed. Biological DMARDs, particularly anti-TNF agents, have shown nodule reduction in case reports and series, presumably through the same inflammatory suppression that drives their primary efficacy.

The methotrexate paradox deserves specific mention because many patients and even some clinicians aren’t aware of it: a documented subset of RA patients develop new nodules, sometimes more numerous and larger than before, after starting methotrexate. This phenomenon - methotrexate-induced nodulosis - can occur even when the arthritis itself is responding well to the drug. The mechanism isn’t completely understood but appears to involve methotrexate’s effects on adenosine signaling in tissue macrophages, altering granuloma organization in a way that promotes rather than suppresses nodule formation.

I took methotrexate earlier in my RA history. If you develop new or worsening subcutaneous nodules after starting methotrexate, it’s worth raising this specifically with your rheumatologist as a potential drug effect rather than attributing it automatically to worsening disease activity.

Hydroxychloroquine (Plaquenil), which I took for many years as part of my RA regimen, has some evidence from case series and small studies for nodule reduction - particularly in the context of methotrexate-induced nodulosis. It’s not a dramatic or guaranteed effect, but it’s a consideration worth discussing if nodules are a concern.

Local corticosteroid injection into a specific symptomatic nodule can reduce its size. Results are variable - some nodules shrink significantly, others don’t respond meaningfully. Injection is typically used for nodules in locations where they cause pain or functional difficulty rather than just cosmetic concern.

Surgical excision is the last resort, and it comes with an important caveat: recurrence is common, sometimes within months of removal. Surgery is generally reserved for nodules causing significant functional impairment - difficulty wearing shoes due to a large heel nodule, grip problems from a large finger nodule - or in locations at high risk of skin breakdown and secondary infection.

The CBD angle: honest about what we know and don’t

There is no direct clinical research on CBD and RA nodules specifically. I’ll be straightforward about that.

What we do know is that CBD modulates inflammatory pathways that are relevant to nodule formation. CB2 receptors are expressed on macrophages, the primary cellular architects of granulomatous inflammation. CBD’s effects on CB2 signaling include reduced TNF-alpha and IL-6 production - the same cytokines that drive the inflammatory environment sustaining nodules. In principle, sustained systemic anti-inflammatory CBD activity could contribute to a less favorable environment for nodule maintenance and expansion.

That’s a mechanistic hypothesis, not evidence from a trial. I take 2800mg broad-spectrum CBD oil daily for systemic RA inflammation management - not specifically targeted at nodules, because I can’t make that claim responsibly. Whether it contributes to keeping overall inflammatory activity lower in ways that incidentally affect nodule activity, I genuinely don’t know.

What I’m confident about: treating RA nodules starts with treating RA effectively. Disease control is the foundation. Everything else is adjunct, and some of those adjuncts - including CBD - have plausible mechanistic relevance even when direct trial evidence doesn’t yet exist.